When was ProLynx founded?

ProLynx was founded in 2009 and raised its 1st funding round 1 year after it was founded.

Where is ProLynx located?

ProLynx is headquartered in San Francisco, United States. It is registered at San Francisco, California.

How many employees does ProLynx have?

As of Jul 31, 2026, the latest employee count at ProLynx is 38.

Is ProLynx a funded company?

ProLynx is a funded company, having raised a total of $70.1M across 5 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on May 21, 2010.

When was the latest funding round of ProLynx?

ProLynx's latest funding was a $***** Series A round on Dec 11, 2025, with participation from 3 investors.

Where does ProLynx rank among its competitors?

ProLynx ranks 33rd amongst 302 active competitors, of which 124 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Adocia, which secured $11.7M in Dec, 2025.

Who are the top competitors of ProLynx?

ProLynx's top competitors include Rhythm Pharmaceuticals, MannKind Corp and Adocia. Among them, Adocia secured the most recent funding round in December, 2025.

ProLynx - 2026 Company Profile, Funding & Competitors

ProLynx is a series A company based in San Francisco (United States), founded in 2009. It operates as an Innovative drug delivery system using pre-programmed linkers for controlled release. ProLynx has raised $70.1M in funding from investors like Orbimed, 5AM Ventures and Monograph. The company has 302 active competitors, including 124 funded and 57 that have exited. Its top competitors include companies like Rhythm Pharmaceuticals, MannKind Corp and Adocia.

Company Details

Innovative drug delivery system using pre-programmed linkers for controlled release. The company develops and licenses a novel β-eliminative drug delivery system. This technology enables controlled, predictable, and sustained release of active drugs, including peptides, proteins, and small molecules, from macromolecular conjugates. The technology overcomes limitations of current half-life extension methods. They focus on creating pre-clinical and clinical candidates for licensing and seek collaborations with academics and pharmaceutical companies to design and prepare drug conjugates. Their technology utilizes self-cleaving linkers to release drugs at specified rates and trigger biodegradation of microspheres after drug release. This innovative approach offers potential advancements in drug delivery and therapeutic outcomes.

Website: prolynxinc.com
Registered Address: San Francisco, California

Key Metrics

Founded Year

2009

Location

San Francisco, United States

Stage

Series A

Total Funding

$70.1M in 5 rounds

Latest Funding Round

Series A, Dec 11, 2025, $*****

Investors

Orbimed & 4 more

Ranked

33^rd among 302 active competitors

Employee Count

38 as on Jul 31, 2026

Similar Companies

Adocia & 259 more

View ProLynx's full profile

ProLynx is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Prolynx Llc CIN: 270333993 , United States, Active	Dec 26, 999	-	8 (As on Dec 31, 2024)	-

ProLynx has raised a total funding of $70.1M over 5 rounds. Its first funding round was on May 21, 2010. Its latest funding round was a Series A round on Dec 11, 2025 for $*****. 3 investors participated in its latest round. ProLynx has 5 institutional investors.

Here is the list of recent funding rounds of ProLynx:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 11, 2025	3922672	Series A	1540953	1087737	9157124	3472460
Sep 10, 2020	6029226	Seed	7768589	7855536	2563528	9637903
Dec 18, 2012	3843224	Grant (prize money)	8007091	1339940	6464490	National Science Foundation

Access funding benchmarks and valuations. Sign up today!

View details of ProLynx's funding rounds and investors

ProLynx's employee count trend

ProLynx has 38 employees as of Jul 26. Here is ProLynx's employee count trend over the years:

Uncover ProLynx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ProLynx include Rhythm Pharmaceuticals, MannKind Corp and Adocia. Here is the list of Top 10 competitors of ProLynx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 9 others	70/100
2nd	MannKind Corp 1991, Los Angeles (United States), Public	Developer of small-molecule drugs	$50M	Colt Ventures, Ignite 500 & 1 others	70/100
3rd	Adocia 2005, Lyon (France), Public	Developer of therapeutics for the treatment of diabetes and obesity	$26M	Stifel, Smalt Capital & 6 others	69/100
4th	Corcept 1998, Menlo Park (United States), Public	Developer of cortisol modulators for the treatment of various diseases	-	Longitude Capital, Cornerstone Capital & 7 others	68/100
5th	Kailera 2024, Waltham (United States), Public	Developer of therapies for treating obesity and related conditions	$1B	Bain Capital Life Sciences, RTW Investments ... & 12 others	65/100
6th	Assembly Biosciences 2005, New York City (United States), Public	Developing novel antivirals to treat serious viral diseases	$700K	Avoro Capital, Armistice Capital & 3 others	65/100
7th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	ATW Partners, Sanofi & 6 others	65/100
8th	Kriya Therapeutics 2012, Redwood City (United States), Series D	Developer of therapeutic solutions for the treatment of diabetes	$938M	Patient Square Capital, Foresite Capital ... & 16 others	64/100
9th	D&D Pharmatech 2014, Seongnam-si (South Korea), Public	Developer of GLP-1-based therapeutics for metabolic disease treatment	$205M	Praxis Capital, Smile Gate Investment & 10 others	64/100
10th	Rani Therapeutics 2012, San Jose (United States), Public	Developer of technology for the oral delivery of large drug molecules	$226M	Shire, Cathay Financial Holdings & 18 others	63/100
33rd	ProLynx 2009, San Francisco (United States), Series A	Innovative drug delivery system using pre-programmed linkers for controlled release	$70.1M	Orbimed, 5AM Ventures & 3 others	56/100